Biosimilar cost savings yet to materialise, says healthcare organisation

Although the biosimilar market in the US is still early in development, US payers believe that the expected cost savings offer ed by biosimilar products have yet to materialise.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Squires refuses to resurrect HydraFacial patent review

22 April 2026 Decision underscores a growing deference to parallel rulings and tighter control over duplicate patent challenges.

Americas

Penile implant maker’s $17m trade secret award unravels

20 April 2026 The maker of a cosmetic penile implant has suffered at the Federal Circuit, after a ruling said its trade secrets claims are not protectable while leaving a counterfeiting finding intact.

Americas

Appeals court eases Teva’s headache with reversal

17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.

More features

Squires refuses to resurrect HydraFacial patent review

Litigator from Brown Rudnick moves firms to chair practice

INTA 2026: In-house tips on what to do in London

Penile implant maker’s $17m trade secret award unravels

Appeals court eases Teva’s headache with reversal

Simmons & Simmons makes senior Asia trademark hire

Baker McKenzie strengthens IP bench with new German lead

Cancer drug researcher hit with suit over mutation-targeting tools

Biosimilar cost savings yet to materialise, says healthcare organisation

More on this story

Editor's picks

Editor's picks

More features